found on the surface of tumor cells and is associated with disease progression and poor prognosis in small cell lung cancer. Ifinatamab deruxtecan is a B7-H3 directed antibody drug conjugate that specifically targets this protein, potentially offering a new treatment option for patients with this challenging disease.
The interim analysis of the IDeate-Lung01 trial showed promising objective response rates with ifinatamab deruxtecan, with a confirmed ORR of 54.8% in the 12 mg/kg dose cohort. The safety profile of the drug was consistent with previous trials, with no new safety signals identified.
These results support further investigation of ifinatamab deruxtecan in patients with extensive-stage small cell lung cancer, and the ongoing IDeate-Lung02 phase 3 trial is evaluating the drug compared to standard chemotherapy in this patient population.
Overall, these findings suggest that ifinatamab deruxtecan has the potential to improve outcomes for patients with small cell lung cancer and address the unmet need for effective treatments in this aggressive disease.